David J. McConkey

ORCID: 0000-0003-1971-0638

Also affiliated with Johns Hopkins Medicine, Sidney Kimmel Comprehensive Cancer Center

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells

(2023)10.1158/1078-0432.c.6519434

Top 100%

0DataRank

Top 100%0 citations

I-Ling Lee, Ali Dadbin, Anita L. Sabichi, Loleta D. Harris, Diana L. Urbauer +5 more

Papers

Driven by 39 papers — median percentile 0. Top paper: “Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605”.

Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605

European Urology(2023)10.1016/j.eururo.2023.08.004

N/A

2.9DataRank · unranked

93 citations

Catherine M. Tangen, Parminder Singh, David J. McConkey, M. Scott Lucia, William T. Lowrance +10 more

A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-2409

N/A

2.8DataRank · unranked

92 citations

Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, Seth P. Lerner, M. Scott Lucia +12 more

Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes

Nature Reviews Urology(2020)10.1038/s41585-020-0304-1

N/A

0.794DataRank · unranked

198 citations

Hikmat Al‐Ahmadie, Bishoy M. Faltas, John A. Taylor, Thomas W. Flaig, David J. DeGraff +5 more

Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)

European Urology(2023)10.1016/j.eururo.2023.06.014

N/A

0.650DataRank · unranked

20 citations

Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, M. Scott Lucia, David J. McConkey +12 more

Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3587

N/A

0.533DataRank · unranked

34 citations

Catherine M. Tangen, Melissa Plets, Gareth Morrison, Alexander Cunha, Tong Xu +16 more

Cell-free DNA methylation as a predictive biomarker of response to neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer in SWOG S1314.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4506

N/A

0.312DataRank · unranked

7 citations

Melissa Plets, Gareth Morrison, Alexander Cunha, Steven Cen, Suhn K. Rhie +11 more

S1314 correlative analysis of ATM, RB1, ERCC2, and FANCC mutations and pathologic complete response (pT0) at cystectomy after neoadjuvant chemotherapy (NAC) in patients with muscle invasive bladder cancer (MIBC): Implications for bladder preservation.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4581

N/A

0.312DataRank · unranked

7 citations

Catherine M. Tangen, Melissa Plets, Rutika Kokate, Joanne Xiu, Chadi Nabhan +9 more

The Bladder Tumor Microenvironment Is a Dynamic Ecosystem: How Microbes, Immunity, and Cancer Converge

European Urology(2025)10.1016/j.eururo.2025.11.009

N/A

0.104DataRank · unranked

1 citations

Jennifer J. Barb, Armine K. Smith, Michael L. Neugent, David J. McConkey

Association between molecular subtype membership or hypoxia-associated gene expression signatures and clinical outcomes in the CALGB 90601 (Alliance) phase 3 clinical trial of gemcitabine and cisplatin (GC) plus bevacizumab (B) or placebo (P).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4562

N/A

0.104DataRank · unranked

1 citations

Woonyoung Choi, Susan Halabi, Bin Luo, Hikmat Al‐Ahmadie, Jonathan E. Rosenberg +12 more

RETRACTED ARTICLE: Re-engineered BCG overexpressing cyclic di-AMP augments trained immunity and exhibits improved efficacy against bladder cancer

Nature Communications(2022)10.1038/s41467-022-28509-z

N/A

0DataRank · unranked

98 citations

Monali Praharaj, Kara A. Lombardo, Takahiro Yoshida, Andrés Matoso, Alex S. Baras +11 more

Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients

Urologic Oncology Seminars and Original Investigations(2022)10.1016/j.urolonc.2022.04.013

N/A

0DataRank · unranked

14 citations

Minhyung Kim, Steven G. Widen, Alexander Yu, Gloria C. Galván, Yunhee Choi-Kuaea +12 more

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.536

N/A

0DataRank · unranked

5 citations

Catherine M. Tangen, Siamak Daneshmand, Ajjai Alva, M. Scott Lucia, David J. McConkey +12 more

Association of DNA damage response (DDR) gene mutations (mts) and response to neoadjuvant cisplatin-based chemotherapy (chemo) in muscle-invasive bladder cancer (MIBC) patients (pts) enrolled onto SWOG S1314.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4522

N/A

0DataRank · unranked

5 citations

Catherine M. Tangen, Michal Sarfaty, Ashley Marie Regazzi, I-Ling C. Lee, Woonyoung Choi +6 more

Characterizing molecular subtypes of high-risk nonmuscle-invasive bladder cancer in African American patients.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.527

N/A

0DataRank · unranked

0 citations

Sungyong You, Minhyung Kim, Steven G. Widen, Alexander Yu, Eduardo Eyzaguirre +10 more

Association of DNA damage repair (DDR) mutations (mts) and clinical outcomes in CALGB 90601 (Alliance).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4521

N/A

0DataRank · unranked

0 citations

Susan Halabi, Bin Luo, Jonathan E. Rosenberg, Woonyoung Choi, Hikmat Al‐Ahmadie +12 more

WITHDRAWN: Recombinant BCG overexpressing a STING agonist elicits trained immunity and improved antitumor efficacy in non-muscle invasive bladder cancer

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.04.25.061531

N/A

0DataRank · unranked

6 citations

Monali Praharaj, Kara A. Lombardo, Takahiro Yoshida, Andrés Matoso, Alex S. Baras +9 more

A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study

European Urology(2023)10.1016/j.eururo.2023.01.017

N/A

0DataRank · unranked

56 citations

Michael A. O’Donnell, Jason A. Efstathiou, Marianna Zahurak, Gary L. Rosner, Jeff Smith +36 more

Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0602

N/A

0DataRank · unranked

19 citations

David J. McConkey, Catherine M. Tangen, Joshua J. Meeks, Thomas W. Flaig, Xing Hua +12 more

Comparison of clinicopathological characteristics, gene expression profiles, mutational analysis, and clinical outcomes of pure and mixed small‐cell carcinoma of the bladder

Histopathology(2023)10.1111/his.14883

N/A

0DataRank · unranked

17 citations

Woonyoung Choi, Mingxiao Feng, Megan Fong, Jean Hoffman‐Censits, Max Kates +7 more

Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonist

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.12.15.571740

N/A

0DataRank · unranked

6 citations

Monali Praharaj, Kara A. Lombardo, Takahiro Yoshida, Andrés Matoso, Alex S. Baras +10 more

Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5080

N/A

0DataRank · unranked

2 citations

Catherine M. Tangen, Melissa Plets, Daniel Bsteh, Tong Xu, Jacek Pinski +13 more

Data from Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells

(2023)10.1158/1078-0432.c.6519434

Top 100%

0DataRank

Top 100%0 citations

I-Ling Lee, Ali Dadbin, Anita L. Sabichi, Loleta D. Harris, Diana L. Urbauer +5 more

Data from γδ T Cells Support Antigen-Specific αβ T cell–Mediated Antitumor Responses during BCG Treatment for Bladder Cancer

(2023)10.1158/2326-6066.c.6550607

N/A

0DataRank · unranked

0 citations

Neelam Mukherjee, Zhen‐Ju Shu, Ryan M. Reyes, Joshua J. Meeks, David J. McConkey +4 more

HERCULES: A prostate cancer (PC) sequencing panel for parallel analysis of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5036

N/A

0DataRank · unranked

0 citations

Jonathan D. Buckley, Dejerianne Ostrow, Jean‐Hugues Parmentier, Smruthi Maganti, Scott A. Mitchell +14 more

Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712

European Urology Oncology(2024)10.1016/j.euo.2024.03.015

N/A

0DataRank · unranked

2 citations

Sophia C. Kamran, Amol C. Shetty, Philip Sutera, Yang Song, Soha Bazyar +29 more

NECTIN-4 PET FOR OPTIMIZING ENFORTUMAB VEDOTIN DOSE-RESPONSE IN UROTHELIAL CARCINOMA

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.12.25.630315

N/A

0DataRank · unranked

2 citations

Ajay Sharma, Kuldeep Gupta, Dhanush R. Banka, Burles A. Johnson, Jeannie Hoffman-Censits +4 more

Inferring Bladder Cancer Evolution from Mucosal Field Effects by Whole-Organ Spatial Mutational, Proteomic, and Metabolomic Mapping

Research Square(2024)10.21203/rs.3.rs-3994376/v1

N/A

0DataRank · unranked

1 citations

Sangkyou Lee, Sung Yun Jung, Paweł Kuś, Jolanta Bondaruk, June Lee +16 more

Urine Tumor DNA to Stratify the Risk of Recurrence in Patients Treated with Atezolizumab for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer

European Urology(2025)10.1016/j.eururo.2025.03.023

N/A

0DataRank · unranked

15 citations

Parminder Singh, David J. McConkey, M. Scott Lucia, Vadim S. Koshkin, Kelly Stratton +16 more

Dysregulated mitochondrial energy metabolism drives the progression of mucosal field effects to invasive bladder cancer

The Journal of Pathology(2025)10.1002/path.6474

N/A

0DataRank · unranked

4 citations

Sung Yun Jung, Paweł Kuś, Jolanta Bondaruk, June Goo Lee, Roman Jaksik +16 more

Sarcomatoid areas of urothelial carcinoma are enriched for CD163‐positive antigen‐presenting cells

The Journal of Pathology Clinical Research(2025)10.1002/2056-4538.70021

N/A

0DataRank · unranked

4 citations

Vamsi Parimi, Sonia Kamanda, David C. Corney, Woonyoung Choi, Jean Hoffman‐Censits +5 more

Combined genomic profiling of cell-free DNA (cfDNA) and circulating tumor cell DNA (ctcDNA) in S1802, a prospective phase 3 trial for metastatic prostate cancer (mHSPC).

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.e17111

N/A

0DataRank · unranked

1 citations

Jonathan D. Buckley, Scott A. Mitchell, Dejerianne Ostrow, Jean‐Hugues Parmentier, Samin Maleki Jahan +13 more

T cell subsets of urine-derived lymphocytes (UDLs) serve as an indicator of TILs and reflect immunological sex differences in bladder cancer

Journal for ImmunoTherapy of Cancer(2025)10.1136/jitc-2025-012050

N/A

0DataRank · unranked

0 citations

No‐Joon Song, Tong Xiao, Timothy D. Gauntner, Kyeong Joo Jung, Emily G Fitts +15 more

Association of molecular subtypes with pathologic response in a phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy (NAC) for localized, muscle-invasive bladder cancer (SWOG S1314; NCT02177695).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5028

N/A

0DataRank · unranked

4 citations

David J. McConkey, Catherine M. Tangen, Joshua J. Meeks, Thomas W. Flaig, Xing Hua +11 more

Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5022

N/A

0DataRank · unranked

55 citations

Catherine M. Tangen, Parminder Singh, David J. McConkey, Scott Lucia, William T. Lowrance +11 more

MP55-18 SARCOMATOID UROTHELIAL CARCINOMA: CLINICO-PATHOLOGICAL ANALYSIS OF 93 CASES WITH EMPHASIS ON PT1 OUTCOMES IN PATIENTS WHO UNDERWENT EARLY CYSTECTOMY AND/OR NEOADJUVANT CHEMOTHERAPY

The Journal of Urology(2020)10.1097/ju.0000000000000924.018

N/A

0DataRank · unranked

0 citations

Kara A. Lombardo, Woonyoung Choi, Trinity J. Bivalacqua, Max Kates, Noah M. Hahn +3 more

Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5506

N/A

0DataRank · unranked

4 citations

Catherine M. Tangen, Melissa Plets, Gareth Morrison, Alexander Cunha, Tong Xu +14 more

BCG invokes superior STING‐mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer

The Journal of Pathology(2021)10.1002/path.5830

N/A

0DataRank · unranked

20 citations

Aleksandar Obradović, Alok Kumar Singh, James L. Liu, Gregory Joice, Max Kates +11 more

γδ T Cells Support Antigen-Specific αβ T cell–Mediated Antitumor Responses during BCG Treatment for Bladder Cancer

Cancer Immunology Research(2021)10.1158/2326-6066.cir-21-0285

N/A

0DataRank · unranked

19 citations

Neelam Mukherjee, Zhen‐Ju Shu, Ryan M. Reyes, Joshua J. Meeks, David J. McConkey +4 more

Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4541

N/A

0DataRank · unranked

27 citations

Catherine M. Tangen, Parminder Singh, David J. McConkey, Scott Lucia, William T. Lowrance +10 more

David J. McConkey

Indexed papers

Top data-sharing exemplar

Papers